Across TCGA pan-cancer cohorts, KMT5A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KMT5A data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KMT5A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated KMT5A expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where KMT5A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	II,III,IV	0.652	0.939	.009	14	view →
LSCC	DFS	Median	All	0.900	0.708	.014	4	view →
GBM	OS	Quartile	All	0.845	1.000	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: KMT5A tumor-vs-normal RNA expression · all KMT5A data types